The PI3K Specific Inhibitor BKM120 Results Effective and Synergizes With Ruxolitinib In Preclinical Models Of Myeloproliferative Neoplasms

被引：7
|
作者：
Bartalucci, Niccolo
Bogani, Costanza
Martinelli, Serena
Mannarelli, Garmela
Villeval, Jean-Luc
Vannucchi, Alessandro M.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1599.1599
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1599
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Effective use of PI3K inhibitor BKM120 to treat human osteosarcoma
    Lu, Yao
    Wang, Qian
    Fan, Shan
    Hu, Bin
    Sun, Liang
    Xue, Hanzhong
    Zhou, Chengpei
    Zhou, Yong
    Zhang, Kun
    Li, Zhong
    Ma, Teng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (04): : 6378 - 6386
  • [2] Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
    Peng, Xin
    Zhang, Shaolu
    Jiao, Wenhui
    Zhong, Zhenxing
    Yang, Yuqi
    Claret, Francois X.
    Elkabets, Moshe
    Wang, Feng
    Wang, Ran
    Zhong, Yuxu
    Chen, Zhe-Sheng
    Kong, Dexin
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [3] Correction to: Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
    Xin Peng
    Shaolu Zhang
    Wenhui Jiao
    Zhenxing Zhong
    Yuqi Yang
    Francois X. Claret
    Moshe Elkabets
    Feng Wang
    Ran Wang
    Yuxu Zhong
    Zhe-Sheng Chen
    Dexin Kong
    Journal of Experimental & Clinical Cancer Research, 40
  • [4] BKM120 is cytotoxic in neuroblastoma targeting the PI3K pathway
    Pomaville, Monica M.
    Zhao, Ping
    Decou, Sarah
    Nagulapally, Abhinav B.
    Bond, Jeffrey
    Sholler, Giselle L. Saulnier
    CANCER RESEARCH, 2016, 76
  • [5] The PI3K inhibitor BKM120 inhibits growth of pancreatic ductal adenocarcinoma in vitro and in vivo
    Tignanelli, Christopher James
    Herrera, Silvia Gabriela
    Torphy, Robert
    Yeh, Jen Jen
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2013, 217 (03) : S137 - S138
  • [6] PRE-CLINICAL ACTIVITY OF THE PI3K INHIBITOR BKM120 ON ACUTE MYELOID LEUKEMIA
    Allegretti, M.
    Ricciardi, M. R.
    Licchetta, R.
    Mirabilii, S.
    Amadori, S.
    Foa, R.
    Tafuri, A.
    HAEMATOLOGICA, 2014, 99 : 291 - 291
  • [7] Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
    Wang, Dong
    Wang, Min
    Jiang, Nan
    Zhang, Yuan
    Bian, Xing
    Wang, Xiaoqing
    Roberts, Thomas M.
    Zhao, Jean J.
    Liu, Pixu
    Cheng, Hailing
    ONCOTARGET, 2016, 7 (11) : 13153 - 13166
  • [8] Effects of the Specific PI3K Inhibitor BKM120, the Dual PI3K/mTOR Inhibitor BEZ235, and Specific mTOR Inhibitors Everolimus and Temsirolimus in Renal and Hepatic Carcinoma Models Resistant to Sunitinib and Sorafenib
    Serova, M.
    Raballand, A.
    Dos Santos, C.
    Riveiro, E.
    Raymond, E.
    Faivre, S.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 113 - 113
  • [9] The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma
    Martin, Sally
    Gan, Zhen Ying
    Fitter, Stephen
    To, Luen B.
    Zannettino, Andrew C. W.
    LEUKEMIA RESEARCH, 2015, 39 (03) : 380 - 387
  • [10] THE PI3K/mTOR INHIBITORS BKM120 AND RAD001 ARE EFFECTIVE AGAINST JAK2V617F MUTATED CELLS AND SYNERGIZE WITH RUXOLITINIB IN IN VITRO AND IN VIVO PRECLINICAL MODELS
    Martinelli, S.
    Bartalucci, N.
    Calabresi, L.
    Bogani, C.
    Balliu, M.
    Guglielmelli, P.
    Bosi, A.
    Vannucchi, A. M.
    HAEMATOLOGICA, 2015, 100 : 108 - 109
12345